Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy  by Kitamura, Hidetsuna et al.
Onset Heart Rate of Microvolt-Level T-Wave
Alternans Provides Clinical and Prognostic
Value in Nonischemic Dilated Cardiomyopathy
Hidetsuna Kitamura, MD, Yoshio Ohnishi, MD, Katsunori Okajima, MD, Akihiko Ishida, MD,
Erdulfo Javier Galeano, MD, Kazumasa Adachi, MD, Mitsuhiro Yokoyama, MD
Kobe, Japan
OBJECTIVES This study was designed to determine the prognostic value of onset heart rate (OHR) in
T-wave alternans (TWA) in patients with nonischemic dilated cardiomyopathy (DCM).
BACKGROUND One of the current major issues in DCM is to prevent sudden cardiac death (SCD). However,
the value of the OHR of TWA as a prognostic indicator in DCM remains to be elucidated.
METHODS We prospectively investigated 104 patients with DCM undergoing TWA testing. The end
point of this study was defined as SCD, documented sustained ventricular tachycardia/
ventricular fibrillation. Relations between clinical parameters and subsequent outcome were
evaluated.
RESULTS Forty-six patients presenting with TWA were assigned to one of the following two subgroups
according to OHR for TWA of 100 beats/min: group A (n  24) with OHR 100
beats/min and group B (n  22) with 100  OHR  110 beats/min. T-wave alternans was
negative in 37 patients (group C) and indeterminate in 21 patients. The follow-up result
comprised 83 patients with determined TWA. During a follow-up duration of 21  14
months, there was a total of 12 arrhythmic events, nine of which included three SCDs in
group A, two in group B and one in group C. The forward stepwise multivariate Cox hazard
analysis revealed that TWA with an OHR 100 beats/min and left ventricular ejection
fraction were independent predictors of these arrhythmic events (p 0.0001 and p 0.0152,
respectively).
CONCLUSIONS The OHR of TWA is of additional prognostic value in DCM. (J Am Coll Cardiol 2002;
39:295–300) © 2002 by the American College of Cardiology
Nonischemic dilated cardiomyopathy (DCM) is a syndrome
characterized by left or biventricular dilatation and systolic
contractile dysfunction, with an incidence of five to eight
cases per 100,000 population per year (1,2). Approximately
50% of patients with recently diagnosed DCM die within
the first year (3), and the distribution between sudden and
non-sudden (heart failure [HF]) deaths is approximately
equal (4). Significant improvements in medical therapy,
such as the development of angiotensin-converting enzyme
inhibitors (5), beta-adrenergic blocking agents (6) and
amiodarone (7) have been shown to improve the prognosis
of patients with congestive HF. However, sudden cardiac
death (SCD) is often the first clinically recognized mani-
festation of heart disease (8). Various approaches for pre-
dicting the risk of SCD, such as electrophysiologic testing
(9,10), signal-averaged electrocardiogram (SAECG) (10–
12), baroreceptor sensitivity (13) and heart rate (HR)
variability (14,15) have been used to identify a high-risk
subgroup. However, the positive predictive value of any of
these measures of risk, used in combination with each other
or with other clinical findings (10–12), has proven insuffi-
cient to predict SCD and, accordingly, to warrant implant-
able cardioverter defibrillator (ICD) therapy. Recently, the
spectral method for detecting microvolt-level T-wave alter-
nans (TWA) was developed. Using this technique, the
presence of subtle alternation in TWA was found to be
strongly associated with inducibility of sustained ventricular
tachycardia/ventricular fibrillation (SVT/VF) and has,
therefore, been proposed as a powerful non-invasive tool for
identifying high-risk patients with ischemic heart disease
(16–21).
T-wave alternans is a threshold phenomenon, which
inversely correlated with the ventricular fibrillation thresh-
old in animal studies (19). Recent studies indicated that
there is a specific HR threshold beyond which TWA
continues to increase with increasing HRs (22,23). The
concurrence of TWA and a sufficiently low HR is reportedly
associated with increased cardiac risk under pathological
conditions (24,25). However, the prognostic value of the
onset heart rate (OHR) of TWA in patients with DCM
remains to be elucidated. Therefore, the goal of this study
was to clarify whether the OHR of TWA is of prognostic
value in patients with DCM.
METHODS
Patient population. We prospectively investigated 104
patients with DCM who were referred to the Kobe Uni-
versity School of Medicine Hospital and Himeji Cardiovas-
cular Center between February 1997 and April 2000. All
patients underwent both non-invasive and invasive evalua-
tion, including TWA during ergometer exercise stress
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testing. All patients were in sinus rhythm. None of the
patients had been treated with beta-blockers, angiotensin-
converting enzyme inhibitors or beta-agonists before entry
to this study. Nonischemic dilated cardiomyopathy was
clinically diagnosed according to the criteria recommended
by the World Health Organization and the National Heart,
Lung and Blood Institute (1). The protocol of the study was
explained to all patients, and informed consent was obtained
from each patient.
Measurement of TWA. T-wave alternans was measured
at rest and during controlled bicycle exercise testing using a
CH 2000 system (Cambridge Heart, Inc., Bedford, Mas-
sachusetts) as previously described (26). The alternans
analysis was performed blind to all clinical data. T-wave
alternans was prospectively defined as positive when it was
sustained with an alternans voltage of 1.9 V during
exercise with an OHR 110 beats/min or below 70% of
maximum predicted HR or 1.0 V at rest for a period of at
least 1 min, provided that the alternans ratio was 3.
T-wave alternans was prospectively defined as negative if
artifact-free criteria were met while the HR was maintained
at a level of 105 beats/min. Otherwise, TWA was defined
as indeterminate (19–21,26,27). The OHR for TWA was
determined during the period when HR was stable and
constant. To define the high-risk subgroup, TWA-positive
patients were categorized according to the following value
based on previous reports (22,28). The predetermined
cut-off point of OHR for TWA of 100 beats/min
represented the division between the two groups; group A
consisted of the patients with OHR 100 beats/min and
group B with 100  OHR  110. T-wave alternans
negative patients were defined as group C.
Measurement of conventional risk markers. Left ventric-
ular end-diastolic diameter (LVDd) and the left ventricular
ejection fraction (LVEF) were calculated by M-mode and
two-dimensional echocardiography. The predetermined
cut-off point of an LVEF 35% was used to define the
high-risk group (29). Patients underwent 24 h of ambula-
tory monitoring during normal daily activities. Non-
sustained ventricular tachycardia (NSVT) was defined as
present if at least one episode of 3 consecutive premature
beats at a rate of 100 beats/min was documented. The
patients underwent SAECG recording. Orthogonal bipolar
X, Y and Z leads were recorded until a noise level of 0.4 V
was reached using the standard techniques (Fukuda Denshi
FDX-6521, Tokyo, Japan). The criteria for abnormality of
the SAECG were defined as previously described (26).
Follow-up. Patients were prospectively followed. Survival
status was obtained by telephone contact with the patients,
their relatives or referring physician and from the review of
hospital records. For patients who died in the hospital or at
home, the cause of death was obtained from medical
records, families and the local physician who had signed the
death certificate. Patients were followed from the day of
TWA testing until they suffered a cardiac event or until the
most recent follow-up appointment. Sustained ventricular
tachycardia was defined as a documented episode of tachy-
cardia of ventricular origin at a rate of 100 beats/min and
lasting for 30 s or resulting in hemodynamic collapse.
Sudden cardiac death was defined as death from unexpected
circulatory arrest, usually due to a cardiac arrhythmia occur-
ring within 1 h of the onset of symptoms. The end point in
this study was defined as SCD or documented SVT/VF.
T-wave alternans determinate patients were analyzed in the
follow-up result. The relationship between clinical param-
eters and subsequent clinical outcome was evaluated.
Statistical analysis. Values are expressed as means  SD
for continuous variables and percentages for categorical
variables. Patient groups were compared by the unpaired t
test for continuous variables and the chi-square test or
Fisher exact test for categorical variables. Event-free curves
were generated using the Kaplan-Meier method, and groups
were compared by the log-rank test. Univariate predictors of
arrhythmic events were evaluated using the Cox propor-
tional hazards model. Significant factors by univariate Cox
regression analysis were reassessed by forward stepwise
selection manner with values for inclusion and elimination
set at p  0.20, respectively. A statistical probability of
0.05 was considered significant.
RESULTS
Study group. The study group consisted of 104 patients
with DCM: 84 men and 20 women with a mean age of
52  15 years. The clinical characteristics of these patients
are shown in Table 1. Upon TWA testing, 70 patients
(84%) were minimally symptomatic (New York Heart
Abbreviations and Acronyms
DCM  nonischemic dilated cardiomyopathy
ICD  implantable cardioverter defibrillator
LVDd  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
NSVT  nonsustained ventricular tachycardia
OHR  onset heart rate
SAECG  signal-averaged electrocardiogram
SCD  sudden cardiac death
SVT/VF  sustained ventricular tachycardia/ventricular
fibrillation
TWA  T-wave alternans
Table 1. Patient Characteristics
Patients (n) 104
Age (yrs) 52  15
Gender: men 84
NYHA 1.68  0.72
NSVT (%) 33 (32%)
Medications at discharge (%)
Digitalis 26 (25%)
Diuretics 49 (47%)
ACE inhibitor 73 (70%)
Beta-blocker 53 (51%)
ACE  angiotensin-converting enzyme; NSVT  non-sustained ventricular tachy-
cardia; NYHA  New York Heart Association class.
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Association functional class I or II), and 13 (16%) had
moderate symptoms (New York Heart Association func-
tional class III); 33 patients (32%) had a previous history of
NSVT before TWA testing. Twenty-one patients were
excluded from further study because of poor electrocardio-
gram recordings with noise (n  4), frequent ectopic beats
(n 10) or a failure to achieve a HR of 105 beats/min (n 
7). Therefore, the follow-up result involved 83 patients.
Arrhythmic events during follow-up. In an average
follow-up of 21  14 months, arrhythmic events were
observed in 12 (14%) of 83 patients. Sudden death occurred
in three patients (4%), one with witnessed cardiac arrest;
two sudden deaths were unwitnessed. Nine patients (11%)
survived an episode of SVT/VF, which was documented by
monitoring electrocardiograms.
Results of TWA measurement. Forty-six patients (44%)
were TWA positive, and 37 (36%) were TWA negative.
T-wave alternans was indeterminate in 21 patients (20%).
T-wave alternans positive patients were classified into the
following two subgroups according to OHR: group A
included 24 patients (23%), and group B had 22 patients
(21%). In both groups, clinical characteristics and the result
of risk stratification tests were comparable (Table 2). There
was no difference between group A and group B in terms of
target HR. The OHR of TWA was not significantly
correlated with the LVEF (r  0.025; p  0.87). There
were nine cardiac events (three SCD, six SVT/VF) in group
A and two (two SVT/VF) in group B. Only a patient in group
C experienced SVT during the follow-up period. Kaplan-
Meier analysis showed that the determination of OHR in
combination with TWA could identify the high-risk subgroup
among 83 DCM patients with TWA determinate results
(log-rank test; p  0.0001) (Fig. 1). Clinical parameters did
not differ significantly between group B and group C, except
for the high incidence of NSVT in group B. The statistical
accuracy of TWA for arrhythmic events was shown in Table 3.
Results of other non-invasive risk stratification tests.
The mean LVEF was 41  13%, and LVDd was 62 
9 mm. During 24-h Holter monitoring, at least one episode
of NSVT was recorded in 36 patients (43%). The SAECG
was positive in 20 patients (24%). The event-free survival for
83 patients with determinate TWA results was examined
according to LVEF, displayed in Figure 2 (log-rank test: p 
0.0087). The statistical accuracy of LVEF, SAECG, LVDd
and NSVT for arrhythmic events is shown in Table 3.
Predictors of arrhythmic events. Univariate predictors of
arrhythmic events are shown in Table 4. Neither age,
gender, systolic blood pressure, diastolic blood pressure,
New York Heart Association (NYHA) functional class nor
SAECG was found to be statistically significant. To im-
prove the predictive accuracy for arrhythmic events, we
performed univariate analyses on the combination of TWA
and OHR and on that of TWA and LVEF. The statistical
accuracy of TWA-positive patients with OHR 100 beats/
min and TWA-positive patients with LVEF 35% for
arrhythmic events is shown in Table 3. T-wave alternans
with OHR 100 beats/min was the best variable model of
the prediction for arrhythmic events. In addition, the Cox
hazard model analysis was used to examine the capability of
identifying a high-risk subgroup within DCM. The forward
stepwise Cox multivariate analysis indicated that TWA with
OHR 100 beats/min and LVEF were independent predic-
tors for identifying high-risk patients with DCM (Table 5).
DISCUSSION
This is the first clinical study to elucidate the prognostic
value of the OHR of TWA in patients with DCM. Our
present study shows that in patients with DCM of low-to-
moderate symptom status, the presence of TWA identified
the arrythmogenic substrate and was associated with a
higher probability of major arrhythmic events. In these
Table 2. Clinical Characteristics and Results of Risk
Stratification Tests for Both Groups
Variables Group A Group B p Value
Patients 24 22
Age 50  17 52  14 NS
HR (beats/min) 77  9 81  9 NS
BP (mm Hg)
Systole 117  22 123  18 NS
Diastole 70  11 75  11 NS
NYHA I/II/III/IV 10/8/6/0 10/7/5/0 NS
Follow-up month 16  14 19  14 NS
Medication
Digitalis 6 5 NS
Diuretics 12 9 NS
ACE 18 15 NS
Beta-blocker 11 10 NS
LVDd (mm) 66  10 63  9 NS
LVEF (%) 36  12 38  14 NS
NSVT  3 (%) 58 68 NS
SAECG (%) 38 18 NS
BP  blood pressure; HR  heart rate; LVDd  left ventricular end-diastolic
diameter; LVEF  left ventricular ejection fraction; NYHA  New York Heart
Association; SAECG signal-averaged electrocardiogram. Other abbreviations as in
Table 1.
Figure 1. The arrhythmia-free survival in 83 patients with determined
T-wave alternans (TWA) results. The event-free probability of patients
with the onset heart rate (OHR) 100 beats/min was significantly lower
than that of patients without OHR 100 beats/min.
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patients, the OHR of TWA added prognostic power to
TWA when compared with LVEF or other risk stratifica-
tion tests and clearly identified those patients with a
potential high risk of SCD.
Additional prognostic value of OHR in DCM. Non-
ischemic dilated cardiomyopathy is a common cause of
congestive HF and represents another important substrate
for ventricular arrhythmia developing into SVT/VF (3).
Significant progress in medical treatment has reduced the
mortality and morbidity of congestive HF (5–7), with nearly
half of all deaths in DCM occurring suddenly due to
SVT/VF (4). Unfortunately, the majority of SCDs occurs
among low-risk patients, including those with NYHA
functional class I or II. The ICD has been reported to be a
beneficial therapy for the secondary prevention of SCD
(30). However, such an effective strategy has limited popu-
lation impact because the current indications for ICD
therapy in patients with DCM include surviving an episode
of cardiac arrest and having syncopal ventricular tachycardia
or non-suppressible hemodynamically compromising ven-
tricular arrhythmia (31). Whether patients with asymptom-
atic NSVT and severe left ventricular dysfunction should
receive an ICD remains unclear as yet. Various non-invasive
tools for determining risk have been reported by numerous
studies, but the positive accuracy of these conventional tests
(9–15) is not yet sufficiently powerful to warrant ICD.
Therefore, the need for a simple and accurate non-invasive
method to stratify large sections of the population at
potential risk from SCD is well recognized, as it would
enable primary prevention. Recently, TWA was proposed as
an effective non-invasive diagnostic tool that identifies
high-risk patients with ischemic heart disease. However,
simply assessing the presence of TWA alone in order to
identify which patients with heart disease are at potential
risk from SCD, presumably in relation to SVT/VF, carries
its own risk in light of low specificity, low positive predictive
value and low predictive accuracy (32) (Table 3).
At first we compared TWA with the SAECG, LVDd,
NSVT, and LVEF of non-invasive risk tests. Grimm et al.
(33) reported that SAECG was not useful for risk stratifi-
cation in light of its low sensitivity (50%) and low positive
predictive value (22%) for serious arrhythmic events during
follow-up. Furthermore, they also reported that the mea-
surements of NSVT and LVDd had univariate statistical
significance, which is consistent with the results of this
study (34). Hoffman et al. (29) reported that 84% of patients
with idiopathic dilated cardiomyopathy with an LVEF
35% died at a mean 39 months, compared with 46% of
patients with an LVEF 35%. Moreover, the preliminary
data of the Marburg Cardiomyopathy study suggests a
higher rate of TWA among patients with idiopathic dilated
cardiomyopathy and an LVEF 30% when compared with
those with an LVEF of 30% (35). Similar to their study,
our data indicates that among the non-invasive tests, TWA
and LVEF were also significant univariate predictors for
arrhythmic events in patients with DCM. In addition,
TWA yielded high sensitivity (92%) but relatively low
specificity (51%), positive predictive value (24%) and pre-
dictive accuracy (57%), although when combined with the
OHR of TWA, the OHR 100 beats/min dramatically
increased the specificity, positive predictive value and pre-
dictive accuracy to 79%, 38% and 78%, respectively. On the
other hand, by combining TWA and LVEF, the specificity
and predictive accuracy improved from 51% to 77% and
from 57% to 75%, respectively, although positive predictive
value changed only slightly (Table 3). The model of the
combination of TWA and OHR was superior to that of
TWA and LVEF for predicting arrhythmic events. Multi-
variate Cox regression analysis showed the greatest benefit
Table 3. TWA, LVEF, SAECG, LVDd, NSVT and the Combination of TWA and the OHR
or LVEF as Predictor of Event-Free Survival
Se Sp PPV NPV PA RR (95% CI)
TWA() 91.7 50.7 23.9 97.3 56.6 8.8 (1.2–65.4)
LVEF  35% 66.7 66.2 25.0 92.2 66.3 3.2 (1.0–9.7)
SAECG 41.7 78.9 25.0 88.9 73.5 2.3 (0.8–6.3)
LVDd  64 mm 66.7 66.2 25.0 92.2 66.3 3.2 (1.0–9.7)
NSVT  3 66.7 60.6 22.2 91.5 61.4 2.6 (0.9–8.0)
TWA() LVEF  35% 58.3 77.5 30.4 91.7 74.5 3.7 (1.3–10.4)
TWA() OHR  100 beats/min 75.0 78.9 37.5 94.9 78.3 7.4 (2.2–24.9)
CI  confidence intervals; NPV  negative predictive value; OHR  onset heart rate; PA  predictive accuracy; PPV 
positive predictive value; RR  relative risk; Se  sensitivity; SP  specificity; TWA  T-wave alternans. Other abbreviations
as in Tables 1 and 2.
Figure 2. The arrhythmia-free survival in 83 patients with determined
T-wave alternans (TWA) results according to left ventricular ejection
fraction (EF).
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in adding OHR to TWA for predicting arrhythmic events
when compared with LVEF (Table 5). The OHR in TWA
was the most powerful tool to stratify the high-risk sub-
group among patients with DCM, and it provided addi-
tional prognostic value in risk stratification.
Potential pathological mechanism linking the OHR of
TWA and SCD in DCM. T-wave alternans is an electro-
cardiogram phenomenon consisting of beat-to-beat changes
in T-wave amplitude and duration of ventricular repolariza-
tion and is associated with vulnerability to ventricular
tachyarrhythmias (16–21). In addition, the reported clinical
factors that modulate TWA are ischemia, HR and sympa-
thetic activation. Among these factors, TWA has also been
reported to be critically dependent on HR and to have a
threshold effect as the HR is elevated (22,23). Pastore et al.
(25) demonstrated that membrane repolarization alternates
with the opposite phase between the neighboring cells (i.e.,
discordant alternans) above a critical HR threshold, which
creates large spatial dispersion of repolarization, developing
into reentrant ventricular fibrillation. Furthermore, recent
studies indicated that TWA is frequently observed at
relatively low HRs under pathological conditions including
a long QT syndrome (24,25). In fact, in this study, those
patients having sustained alternans occurring with the OHR
100 beats/min had a high incidence of severe ventricular
tachycardia. In addition, our results demonstrated that the
determination of OHR concomitantly with the presence of
TWA made the specificity, positive predictive value and
predictive accuracy improve dramatically in predicting ar-
rhythmic events in DCM. Thus, the OHR of TWA
appears to be a useful tool in identifying the presence of
arrhythmogenic substrate, the probability of an arrhythmia-
initiating event and vulnerability of substrate to initiating
events. It has not been sufficiently evaluated why lower HR
thresholds for alternans increase cardiac risk, especially ar-
rhythmic risk under pathological circumstances, but its poten-
tial mechanism may be mainly due to an underlying distur-
bance in cardiac repolarization that is dependent on HR, in
that impaired functions of several ion channels involving the
potassium channel, sodium channel or sodium channel elec-
trogenically interacting with the calcium channel probably
reduce the HR threshold required to elicit TWA (24,25,36).
Implications of this study. In the prognostic non-invasive
clinical procedures of risk stratification in DCM, the detec-
tion of TWA plays a fundamental role in identifying those
patients at a potential high risk of SCD. T-wave alternans
testing was the best risk stratification method for predicting
arrhythmic events in DCM, consistent with previous studies
(16–21,23,24,26,35,37,38). Furthermore, in this study, the
OHR of TWA provided new information on the risk
stratification of patients with DCM. Given the available
data, we speculate that the OHR provoking TWA in this
prognostic stratification of patients with DCM is strictly
linked to electrical instability, arrythmogenic substrate and
the underlying disturbance in cardiac repolarization. Our
study suggests that the OHR of TWA should be taken into
consideration when stratifying the high-risk subgroup in
DCM. Therefore, the determination of the OHR in TWA
must be the primary preventative approach for the indica-
tion of ICD implantation in patients with DCM. By further
electrophysiological investigations, the role of OHR as an
inducer of TWA in the pathogenesis of DCM will provide
an important insight into the mechanism of SCD.
Study limitations. Several limitations should be acknowl-
edged in this study. One limitation was the low number of
arrhythmic events, which may determine instability of the
results by multivariate analysis. Second, within the sample
population, the cut-off point of OHR for TWA was defined
as100 beats/min, which worked well in differentiating the
high-risk subgroup from the low-to-moderate-risk patients
with DCM. Third, many of the patients with DCM had
atrial fibrillation, frequent ectopic beats or were pacemaker-
dependent. Therefore, we had to exclude them because it
was not possible to analyze their electrocardiograms. How-
ever, such patients, in light of the clinical course, are
considered to be high-risk, and they are less likely to suffer
SCD due to SVT/VF.
Table 4. Univariate Predictors of Arrhythmic Events in Dilated Cardiomyopathy Patients With
Determinate TWA Results
Prediction of Arrhythmic Events
Variables Parameter Estimate Hazard Ratio 95% CI p Value
NSVT 1.2220 3.39 1.01 to 11.39 0.0479
LVDd 0.0571 1.06 1.00 to 1.12 0.0368
TWA 2.4765 11.90 1.53 to 92.59 0.0180
LVEF 0.0681 0.93 0.89 to 0.98 0.0108
TWA() LVEF  35% 1.6161 5.03 1.58 to 16.01 0.0062
TWA() OHR  100 beats/min 2.2759 9.79 2.62 to 36.21 0.0007
Abbreviations as in Tables 1 to 3.
Table 5. Multivariate Predictors of Arrhythmic Events in
Dilated Cardiomyopathy Patients With Determinate
TWA Results
Variables
Parameter
Estimate
Hazard
Ratio 95% CI
p
Value
LVEF 0.06523 0.94 0.89 to 0.99 0.0152
TWA() OHR
 100 beats/min
2.18983 8.93 2.38 to 33.52 0.0001
Abbreviations as in Tables 1 to 4.
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Conclusions. T-wave alternans is a powerful risk stratifier
for patients potentially at risk from SCD. The OHR of
TWA has additional prognostic value in patients with
DCM. Therefore, it appears likely that it will be the most
useful clinical predictor of subsequent arrhythmic events in
low-to-moderate-risk patients with DCM.
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